Table 2.
Baseline differences in secondary cardiac injury biomarkers between COVID-19 survivors and nonsurvivors.
| Biomarker | Studies | Patients | Heterogeneity | SMD (95% CI) | P | |||
|---|---|---|---|---|---|---|---|---|
| Nonsurvivors | Survivors | Total | Model | I 2 (%) | ||||
| CK-MB | 2 | 48 | 123 | 171 | F | 0 | 0.97 (0.62, 1.32) | <0.0001 |
| hs-CRP | 5 | 231 | 595 | 826 | R | 99 | 2.78 (0.90, 4.65) | 0.004 |
| IL-6 | 3 | 137 | 306 | 443 | R | 99 | 3.13 (0.24, 6.03) | 0.03 |
| Myoglobin | 2 | 89 | 240 | 329 | R | 99 | 3.00 (−1.36, 7.36) | 0.18 |
CI, confidence interval; CK-MB, creatine kinase-myocardial bound; CRP, C-reactive protein; F, fixed-effects model; IL-6, interleukin-6; R, random-effects model; SMD, standardized mean difference.